Artelo Biosciences Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline features ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist in Phase 1b/2a clinical trials for treating cancer-related anorexia and weight loss. ART12.11, a proprietary cannabidiol cocrystal with tetramethylpyrazine, targets anxiety, depression, post-traumatic stress disorder, epilepsy, insomnia, pain, and inflammation. ART26.12, a fatty acid binding protein 5 inhibitor, addresses chemotherapy-induced peripheral neuropathy, diabetic neuropathy, osteoarthritis pain, prostate and breast cancer, dermatologic conditions, and anxiety disorders. These candidates aim to fulfill unmet medical needs in oncology supportive care, neurology, psychiatry, and pain management. Founded in 2011 and headquartered in Solana Beach, California, Artelo Biosciences Inc. applies advanced scientific and regulatory expertise to advance its portfolio of innovative, proprietary therapies.